↓ Skip to main content

Dove Medical Press

Article Metrics

Tapentadol extended release in the management of peripheral diabetic neuropathic pain

Overview of attention for article published in Therapeutics and Clinical Risk Management, January 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
9 tweeters

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
53 Mendeley
Title
Tapentadol extended release in the management of peripheral diabetic neuropathic pain
Published in
Therapeutics and Clinical Risk Management, January 2015
DOI 10.2147/tcrm.s32193
Pubmed ID
Authors

Nalini Vadivelu, Benjamin Maslin, Alice Kai, Aron Legler, Gopal Kodumudi, Jack Berger

Abstract

Tapentadol, a μ-opioid agonist and norepinephrine reuptake inhibitor, has been found to be an effective medication for a wide variety of chronic pain conditions, including back pain, cancer-related pain, and arthritic pain. It has also been found to have fewer gastrointestinal side effects than more traditional opioid-based therapies. More recently, tapentadol extended release has been demonstrated to be effective in the management of painful diabetic neuropathy, an often debilitating condition affecting approximately one-third of all patients with diabetes. This review highlights the most up-to-date basic and clinical studies by focusing on the mechanisms of action of tapentadol and its clinical efficacy, especially with regard to painful diabetic neuropathy.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 53 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 17%
Student > Doctoral Student 6 11%
Researcher 6 11%
Student > Ph. D. Student 5 9%
Student > Postgraduate 4 8%
Other 12 23%
Unknown 11 21%
Readers by discipline Count As %
Medicine and Dentistry 23 43%
Pharmacology, Toxicology and Pharmaceutical Science 6 11%
Nursing and Health Professions 3 6%
Immunology and Microbiology 2 4%
Agricultural and Biological Sciences 1 2%
Other 2 4%
Unknown 16 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2015.
All research outputs
#3,002,636
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#149
of 922 outputs
Outputs of similar age
#60,403
of 268,668 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#6
of 28 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,668 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.